Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 6, 2015, Pages 2018-2023

  Alcolea, Daniel ^a,b   Vilaplana, Eduard ^a,b   Pegueroles, Jordi ^a,b   Montal, Victor ^a,b   Sánchez Juan, Pascual ^b,c   González Suárez, Andrea ^b,c   Pozueta, Ana ^b,c   Rodríguez Rodríguez, Eloy ^b,c   Bartrés Faz, David ^d,e   Vidal Piñeiro, Dídac ^d,e   González Ortiz, Sofía ^f   Medrano, Santiago ^f   Carmona Iragui, María ^a,b   Sánchez Saudinós, MaBelén ^a,b   Sala, Isabel ^a,b   Anton Aguirre, Sofía ^a,b   Sampedro, Frederic ^a   Morenas Rodríguez, Estrella ^a,b   Clarimón, Jordi ^a,b   Blesa, Rafael ^a,b   Lleó, Alberto ^a,b   Fortea, Juan ^a,b   more..

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f HOSPITAL DEL MAR   (Spain)

Author keywords

Cortical thickness; CSF biomarkers; Neuroinflammation; Preclinical Alzheimer's disease; Structural MRI; YKL 40

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CHITINASE; PROTEIN YKL 40; TAU PROTEIN; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN; LECTIN;

ADULT; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; AGED; ATROPHY; BRAIN CORTEX; CEREBROSPINAL FLUID; INFLAMMATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ADIPOKINES; AGED; ALZHEIMER DISEASE; ATROPHY; BIOMARKERS; CEREBRAL CORTEX; FEMALE; HUMANS; INFLAMMATION; LECTINS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; TAU PROTEINS;

EID: 84929288330     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.03.001     Document Type: Article

References (31)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
2. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
3. Alcolea D., Carmona-Iragui M., Suárez-Calvet M., Sánchez-Saudinós M.B., Sala I., Antón-Aguirre S., Blesa R., Clarimón J., Fortea J., Lleó A. Relationship between β-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. J.Alzheimers Dis. 2014, 42:157-167.
4. Alcolea D., Martínez-Lage P., Izagirre A., Clerigué M., Carmona-Iragui M., Alvarez R.M., Fortea J., Balasa M., Morenas-Rodríguez E., Lladó A., Grau O., Blennow K., Lleó A., Molinuevo J.L. Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain. J.Alzheimers Dis. 2014, 39:719-726.
5. Antonell A., Mansilla A., Rami L., Lladó A., Iranzo A., Olives J., Balasa M., Sánchez-Valle R., Molinuevo J.L. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J.Alzheimers Dis. 2014, 42:901-908.
6. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
7. Buerger K., Ewers M., Pirttilä T., Zinkowski R., Alafuzoff I., Teipel S.J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
8. Craig-Schapiro R., Perrin R.J., Roe C.M., Xiong C., Carter D., Cairns N.J., Mintun M.A., Peskind E.R., Li G., Galasko D.R., Clark C.M., Quinn J.F., D'Angelo G., Malone J.P., Townsend R.R., Morris J.C., Fagan A.M., Holtzman D.M. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol. Psychiatry 2010, 68:903-912.
9. Del Campo M., Mollenhauer B., Bertolotto A., Engelborghs S., Hampel H., Simonsen A.H., Kapaki E., Kruse N., Le Bastard N., Lehmann S., Molinuevo J.L., Parnetti L., Perret-Liaudet A., Sáez-Valero J., Saka E., Urbani A., Vanmechelen E., Verbeek M., Visser P.J., Teunissen C. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark. Med. 2012, 6:419-430.
10. Desikan R.S., McEvoy L.K., Thompson W.K., Holland D., Roddey J.C., Blennow K., Aisen P.S., Brewer J.B., Hyman B.T., Dale A.M. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann. Neurol. 2011, 70:657-661.
11. Dickerson B.C., Bakkour A., Salat D.H., Feczko E., Pacheco J., Greve D.N., Grodstein F., Wright C.I., Blacker D., Rosas H.D., Sperling R.a, Atri A., Growdon J.H., Hyman B.T., Morris J.C., Fischl B., Buckner R.L. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 2009, 19:497-510.
12. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 2009, 65:176-183.
13. Fagan A.M., Mintun M.a, Mach R.H., Lee S.-Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between invivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
14. Fagan A.M., Perrin R.J. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark. Med. 2012, 6:455-476.
15. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11050-11055.
16. Fortea J., Vilaplana E., Alcolea D., Carmona-Iragui M., Sánchez-Saudinos M.-B., Sala I., Antón-Aguirre S., González S., Medrano S., Pegueroles J., Morenas E., Clarimón J., Blesa R., Lleó A. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann. Neurol. 2014, 2:223-230.
17. Hurtado D.E., Molina-Porcel L., Iba M., Aboagye A.K., Paul S.M., Trojanowski J.Q., Lee V.M.-Y Aß accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am. J. Pathol. 2010, 177:1977-1988.
18. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
19. Mattsson N., Andreasson U., Persson S., Carrillo M.C., Collins S., Chalbot S., Cutler N., Dufour-Rainfray D., Fagan A.M., Heegaard N.H.H., Robin Hsiung G.-Y., Hyman B., Iqbal K., Lachno D.R., Lleó A., Lewczuk P., Molinuevo J.L., Parchi P., Regeniter A., Rissman R., Rosenmann H., Sancesario G., Schröder J., Shaw L.M., Teunissen C.E., Trojanowski J.Q., Vanderstichele H., Vandijck M., Verbeek M.M., Zetterberg H., Blennow K., Käser S.A. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013, 9:251-261.
20. Mattsson N., Insel P., Nosheny R., Trojanowski J.Q., Shaw L.M., Jack C.R., Tosun D., Weiner M. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol. Aging 2014, 35:614-622.
21. Mattsson N., Tabatabaei S., Johansson P., Hansson O., Andreasson U., Månsson J.-E., Johansson J.-O., Olsson B., Wallin A., Svensson J., Blennow K., Zetterberg H. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med. 2011, 13:151-159.
22. McGeer P.L., McGeer E.G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013, 126:479-497.
23. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
24. Olsson B., Hertze J., Lautner R., Zetterberg H., Nägga K., Höglund K., Basun H., Annas P., Lannfelt L., Andreasen N., Minthon L., Blennow K., Hansson O. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J.Alzheimers Dis. 2013, 33:45-53.
25. Paterson R.W., Bartlett J.W., Blennow K., Fox N.C., Shaw L.M., Trojanowski J.Q., Zetterberg H., Schott J.M. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl. Psychiatry 2014, 4:e419.
26. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J.Intern. Med. 2004, 256:183-194.
27. R: A Language and Environment for Statistical Computing 2014, R Core Team, Available at: http://www.r-project.org/. Accessed February 16, 2015.
28. Sala I., Sánchez-Saudinós M.B., Molina-Porcel L., Lázaro E., Gich I., Clarimón J., Blanco-Vaca F., Blesa R., Gómez-Isla T., Lleó A. Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. Dement. Geriatr. Cogn. Disord. 2008, 26:506-512.
29. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
30. Strozyk D., Blennow K., White L.R., Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
31. Tapiola T., Alafuzoff I., Herukka S.-K., Parkkinen L., Hartikainen P., Soininen H., Pirttilä T. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 2009, 66:382-389.